Article Type
Changed
Display Headline
Genetic Marker Suggests INFβ Response
Role of SLC9A9 in treatment efficacy in MS

An intronic variant in SLC9A9 (rs9828519) is associated with nonresponse to interferon-β (INFβ) in patients with multiple sclerosis (MS), according to a genome-wide association study.

Researchers confirmed the association in a meta-analysis across 3 replication data sets and found the SLC9A9 mRNA expression is diminished in MS subjects who are more likely to have relapses. 

In addition, SLC9A9 knockdown in T cells in vitro leads to an increase in expression of proinflammatory molecule IFNϒ.

Citation: Esposito F, Sorosina M, Ottoboni L, et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. 2015;78(1):115-127. doi: 10.1002/ana.24429.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
SCL9A9 and Interferon
Author and Disclosure Information

Author and Disclosure Information

Role of SLC9A9 in treatment efficacy in MS
Role of SLC9A9 in treatment efficacy in MS

An intronic variant in SLC9A9 (rs9828519) is associated with nonresponse to interferon-β (INFβ) in patients with multiple sclerosis (MS), according to a genome-wide association study.

Researchers confirmed the association in a meta-analysis across 3 replication data sets and found the SLC9A9 mRNA expression is diminished in MS subjects who are more likely to have relapses. 

In addition, SLC9A9 knockdown in T cells in vitro leads to an increase in expression of proinflammatory molecule IFNϒ.

Citation: Esposito F, Sorosina M, Ottoboni L, et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. 2015;78(1):115-127. doi: 10.1002/ana.24429.

An intronic variant in SLC9A9 (rs9828519) is associated with nonresponse to interferon-β (INFβ) in patients with multiple sclerosis (MS), according to a genome-wide association study.

Researchers confirmed the association in a meta-analysis across 3 replication data sets and found the SLC9A9 mRNA expression is diminished in MS subjects who are more likely to have relapses. 

In addition, SLC9A9 knockdown in T cells in vitro leads to an increase in expression of proinflammatory molecule IFNϒ.

Citation: Esposito F, Sorosina M, Ottoboni L, et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. 2015;78(1):115-127. doi: 10.1002/ana.24429.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Genetic Marker Suggests INFβ Response
Display Headline
Genetic Marker Suggests INFβ Response
Legacy Keywords
SCL9A9 and Interferon
Legacy Keywords
SCL9A9 and Interferon
Article Source

PURLs Copyright

Inside the Article